Navigation Links
Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
Date:3/13/2008

>-- Raised $24.8 million in two successful public offerings

Strengthened Intellectual Property Portfolio:

-- Granted a U.S. patent for HPV fusions to treat patients with HPV-

related diseases

-- Granted a U.S. patent covering heat shock protein fusions to treat

anogenital warts

-- Won an important challenge to two U.S. patents; U.S. Patent and

Trademark Office reissued composition of matter and methods of use for

Company's CoVal(TM) fusions

-- Granted European patent covering CoVal(TM) fusion proteins to treat

influenza

Gregory M. McKee, President and Chief Executive Officer at Nventa commented on the year: "2007 was a year of significant events at Nventa. We are very pleased with the progress we made during the past year as we advanced new HspE7 (HspE7 + Poly-ICLC) into a Phase 1 clinical trial and completed the safety evaluation for three of the four cohorts in the trial. We anticipate completing the evaluation of the remaining cohort by the end of the second quarter of 2008, and are working diligently to design the Phase 2 clinical program, expected to begin shortly after this Phase 1 trial, to test new HspE7 in a larger population of patients with cervical dysplasia." Mr. McKee continued, "With the strength of our Directors, the addition of two new senior managers and the creation of a distinguished board of international experts, we look forward to building additional value for our shareholders through the continued advancement of new HspE7 for human papillomavirus (HPV)-related diseases."

Total Year 2007 and Fourth Quarter Financial Results:

All amounts, unless specified otherwise, are in Canadian dollars.

Nventa reported a net loss of $12,413,000, or $0.06 per share, for the year ended December 31, 2007, compared to a net loss of $10,067,000, or $0.12 per share, for the same period in 2006. The increase in net loss in 2007 from 2006 is principally re
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
2. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
3. Nventa updates progress of cervical dysplasia trial with new HspE7
4. Nventas CEO to present at two upcoming investor conferences
5. Nventa announces publication of HspE7 data
6. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
7. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
8. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... DC (PRWEB) January 14, 2014 Carahsoft ... for Thursday, January 23, 2014 at 2pm EST (11am ... Knowledge.” The topic focuses on how technology can turn ... critical decisions for government agencies. The online webinar will ...
(Date:1/14/2014)... Texas , Jan. 14, 2014 The ... and research medicinal plants and therapeutic derivatives thereof ... health professionals, and researchers about the challenges of ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), ... solutions for patients, physicians, the biopharmaceutical industry, regulators, ... the signing of a three-year Research Collaboration Agreement ... (FDA). This initiative is designed to generate ...
(Date:1/14/2014)... 14, 2014 Independent publisher Bitingduck Press, ... Montreal, Canada, has big ideas for 2014 in production ... goals are to produce high-quality, low-cost, DRM-free ebooks and ... businesses. , The first major development will be ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... Caffeine Test Strips, to Know for Sure, Studies show that ... ... levels of caffeine, MONROVIA, Calif., Nov. 12 Ever wonder whether ... for sure,with new D+CAF, the first ever do-it-yourself caffeine test strip from,Silver ...
... MaxCyte, Inc.,the pioneer in scalable, high performance ... a live discussion with industry experts on the,challenges ... discussion is open to the industry and will ... 2:00-3:00EST., One of the respected industry experts ...
... Implementation Issues and Recommendations, BETHLEHEM, Pa., ... of Clinical Value Marketing, Infusion Systems Division ... Services for B. Braun Medical,Inc. (B. Braun), ... and services,recently represented B. Braun at the ...
Cached Biology Technology:Is Your Decaf Really Decaf? 2MaxCyte Hosts Live Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery 2B. Braun Directors Participate at First ISMP National Smart Pump Safety Summit 2B. Braun Directors Participate at First ISMP National Smart Pump Safety Summit 3
(Date:7/9/2014)... bladders of healthy women differ from bacteria in ... to researchers from Loyola University Chicago Stritch School ... 9, 2014, in the American Society for Microbiology,s ... communities may play a role in female urinary ... common, yet poorly understood, condition with symptoms similar ...
(Date:7/9/2014)... Centre (CNIO) have discovered that NANOG, an essential gene ... stratified epitheliathose that form part of the epidermis of ... adult organisms. According to the conclusions of the study, ... factor could also play a role in the formation ... and skin. , The pluripotency factor NANOG is active ...
(Date:7/9/2014)... studying critically ill children with traumatic injuries have ... are likely to develop a hospital-acquired infection. The ... and published online in June in the journal ... efforts that could lead to the clinical implementation ... prevent or reverse immune system damage following critical ...
Breaking Biology News(10 mins):CNIO scientists discover that pluripotency factor NANOG is also active in adult organisms 2Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3
... Dana-Farber Cancer Institute (Dana-Farber), Burnham Institute for Medical ... and Prevention (CDC) have reported the identification of ... range of influenza A viruses, including avian influenza ... some seasonal influenza viruses. These antibodies have the ...
... International, Inc. (OTC Bulletin Board: BKYI), a leader in ... today that it will participate in Imperial Capital,s Homeland ... of March. Additional details regarding BIO-key,s participation at ... , Imperial Capital,s ...
... Permanently Disposes Magnetically Recorded Data to Help QSGI,s ... Calif., Feb. 18 Fujitsu Computer Products of ... products including hard disk drives, peripherals and biometric ... using the Fujitsu Mag EraSURE degaussing ...
Cached Biology News:Scientists identify human monoclonal antibodies effective against bird and seasonal flu viruses 2Scientists identify human monoclonal antibodies effective against bird and seasonal flu viruses 3BIO-key(R) Announces Conference Schedule 2QSGI Integrates Fujitsu Mag EraSURE Data Degausser into its Suite of Information Technology Security Services 2QSGI Integrates Fujitsu Mag EraSURE Data Degausser into its Suite of Information Technology Security Services 3QSGI Integrates Fujitsu Mag EraSURE Data Degausser into its Suite of Information Technology Security Services 4QSGI Integrates Fujitsu Mag EraSURE Data Degausser into its Suite of Information Technology Security Services 5
... The dsRNA Marker consists of ten ... 200, 300, 400, 500 and 1,000 base ... size marker for determinating sizes of double-stranded ... in the dsRNA Marker is adjusted to ...
... size markers are a mixture of Strep•Tag® ... 100 kDa. The markers provide precise size ... staining with Coomassie blue. Because each of ... the markers can also be detected by ...
Mouse monoclonal antibody to ACP2 - acid phosphatase 2, lysosomal...
... V, is used for agitation and mixing applications ... and destaining of gels and blots, and Southern ... rpm) and can handle a maximum load of ... 29 x 21 cm platforms covered with nonslip ...
Biology Products: